Neurodevelopmental Study in HIV-infected Ugandan Children

1
Neurodevelopmental Study in HIV-infected Ugandan
Children

• Hannah Boal
• 1/11/07

2
Background

• HIV encephalopathy is a major cause of morbidity
  from HIV-1 infection
• Children with advanced HIV-disease are profoundly
  neurodevelopmentally delayed
• Data about those with mild disease are sparse
• Most data based on subtype B infection in the US
  and Western Europe

3
Study Aims

• Determine if HIV-infected Ugandan children with
  mild or no immune suppression are
  neurodevelopmentally delayed compared to HIV(-)
  children.
• Determine, within HIV-infected Ugandan children
  with mild or no immune suppression, the
  predictors of neurocognitive dysfunction (HIV
  plasma RNA level, HIV subtype, HIV DNA level).

4
Method

• Subjects
• 150 CHAMP children, CD4gt15, ART naïve
• 80 UO1 children
• Patients pre-selected , matched for age- and
  gender
• Testing scheduled around routine visits
• Performed by Paul Bangriana and his assistants

5
Neuropsychological Testing

• Parent Questionnaire and Home Evaluation
• Neuropsychological Testing
• 2 to 6 yo
• Mullen Early Learning Scales (cognitive/motor)
• Early Childhood Vigilance Test (attention)
• Color-Object Association Test (memory)
• 6-10 yo
• Modified Kaufman Assessment Battery (cognitive)
• TOVA (visual and auditory attention)
• Bruininks-Oseretsky (motor)
• Testing should take 1 - 3 hours depending on the
  age of the child

6
Time Line

• UCSF IRB contingent approval
• Nov-Dec
• MUREC/UNCST application review
• Subject selection, scheduling
• Dec-onward
• Enrollment/testing
• Initially one child tested per day, with an
  increase in frequency as personnel and space
  allows